Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IBI129 |
Synonyms | |
Therapy Description |
Limited information is currently available on IBI129, a putative CD276 (B7-H3) antibody-drug conjugate (ADC) (Sep 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI129 | IBI 129|IBI-129 | CD276 Antibody 12 | Limited information is currently available on IBI129, a putative CD276 (B7-H3) antibody-drug conjugate (ADC) (Sep 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05991349 | Phase Ib/II | IBI129 | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |